Efficacy and safety of Dang Gui Yinzi combined with topical medications for psoriasis: A systematic review and meta-analysis

Pharmacological Research - Modern Chinese Medicine Pub Date : 2025-06-04 DOI:10.1016/j.prmcm.2025.100637

Li Liang , Zhaohui Hou , Lian Zhang , Ying Sun

{"title":"Efficacy and safety of Dang Gui Yinzi combined with topical medications for psoriasis: A systematic review and meta-analysis","authors":"Li Liang , Zhaohui Hou , Lian Zhang , Ying Sun","doi":"10.1016/j.prmcm.2025.100637","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Psoriasis, a chronic inflammatory skin disease, is traditionally classified as \"leukoderma\" or \"tinea cruris\" in Traditional Chinese Medicine (TCM). Dang Gui Yinzi (Dang Gui Drink, DGD), a classic TCM formula, is prescribed to nourish blood, dispel wind, and alleviate dryness, aligning with TCM pathogenesis theories of psoriasis.</div></div><div><h3>Methods</h3><div>A systematic review and meta-analysis of randomized controlled trials (RCTs) focusing on the efficacy and safety of Dang Gui Drink combined with topical medications for psoriasis was conducted. This meta-analysis was performed based on a protocol registered in PROSPERO (CRD42025637050). The outcomes were reported as mean differences (MDs) with corresponding 95 % confidence intervals (CI) or risk ratio (RR) with 95 % CI.</div></div><div><h3>Results</h3><div>A total of 13 RCTs, involving 918 participants, were included. The MD for Psoriasis Area and Severity Index (PASI) score improvement was −3.26 (95 % CI [−4.13 to −2.39]), indicating a significant improvement in the combination therapy group compared to the control group. The RR for clinical efficacy was 1.27 (95 % CI [1.19 to 1.36]), suggesting higher efficacy in the combination therapy group. There was no significant difference in the incidence of adverse events (RR = 0.51, 95 % CI [0.16 to 1.62])<em>.</em></div></div><div><h3>Discussion</h3><div>Dang Gui Drink combined with topical therapies demonstrates enhanced efficacy for psoriasis with a favorable safety profile. However, further high-quality RCTs are needed to enhance the robustness and reliability of these findings.</div><div>© 2012 Published by Elsevier Ltd. Selection and/or peer-review under responsibility of Global Science and Technology Forum Pte Ltd</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"16 ","pages":"Article 100637"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological Research - Modern Chinese Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667142525000661","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Psoriasis, a chronic inflammatory skin disease, is traditionally classified as "leukoderma" or "tinea cruris" in Traditional Chinese Medicine (TCM). Dang Gui Yinzi (Dang Gui Drink, DGD), a classic TCM formula, is prescribed to nourish blood, dispel wind, and alleviate dryness, aligning with TCM pathogenesis theories of psoriasis.

Methods

A systematic review and meta-analysis of randomized controlled trials (RCTs) focusing on the efficacy and safety of Dang Gui Drink combined with topical medications for psoriasis was conducted. This meta-analysis was performed based on a protocol registered in PROSPERO (CRD42025637050). The outcomes were reported as mean differences (MDs) with corresponding 95 % confidence intervals (CI) or risk ratio (RR) with 95 % CI.

Results

A total of 13 RCTs, involving 918 participants, were included. The MD for Psoriasis Area and Severity Index (PASI) score improvement was −3.26 (95 % CI [−4.13 to −2.39]), indicating a significant improvement in the combination therapy group compared to the control group. The RR for clinical efficacy was 1.27 (95 % CI [1.19 to 1.36]), suggesting higher efficacy in the combination therapy group. There was no significant difference in the incidence of adverse events (RR = 0.51, 95 % CI [0.16 to 1.62]).

Discussion

Dang Gui Drink combined with topical therapies demonstrates enhanced efficacy for psoriasis with a favorable safety profile. However, further high-quality RCTs are needed to enhance the robustness and reliability of these findings.

Abstract Image

查看原文本刊更多论文

党归饮子联合外用药物治疗银屑病的疗效和安全性：系统评价和荟萃分析

银屑病是一种慢性炎症性皮肤病，传统上在中医中被归类为“白皮病”或“癣”。党归饮是一种经典的中医方剂，具有养血、祛风、平燥的功效，符合银屑病的中医病机理论。方法对党归饮联合外用药物治疗银屑病的疗效和安全性进行随机对照试验的系统评价和meta分析。本荟萃分析基于在PROSPERO （CRD42025637050）注册的方案进行。结果报告为平均差异（md），对应95%置信区间（CI）或95% CI的风险比（RR）。结果共纳入13项随机对照试验，918名受试者。银屑病面积和严重程度指数（PASI）评分改善的MD为- 3.26 (95% CI[- 4.13至- 2.39])，表明联合治疗组与对照组相比有显著改善。临床疗效RR为1.27 (95% CI[1.19 ~ 1.36])，提示联合治疗组疗效更高。两组不良事件发生率差异无统计学意义（RR = 0.51, 95% CI[0.16 ~ 1.62]）。当归饮联合局部治疗对银屑病的疗效增强，安全性良好。然而，需要进一步的高质量随机对照试验来提高这些发现的稳健性和可靠性。©2012 Elsevier Ltd.出版由环球科技论坛私人有限公司负责甄选及/或同行评审

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacological Research - Modern Chinese Medicine

CiteScore

1.60

自引率

0.00%

发文量